EUVIMEDEUVIMED entdecken
Crossref

Temsirolimus safety evaluation: real-world adverse event analysis from the FDA adverse event reporting system database

Lifeng Dan, Zhenyu Liu, Zecang Zhao, Yueli Ran, Jiangtao Zhou, Dongyang Li, Renjie Zhou, Shuai Su, Zhikang Yin

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-06 · 399 (9) · 13661-13676

DOI: 10.1007/s00210-026-05233-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 30.03.2026. Verfasst von Lifeng Dan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China. Hauptthemen laut MEDLINE: Sirolimus, Adverse Drug Reaction Reporting Systems, MTOR Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 93 Literaturangaben. Gefördert von: Natural Science Foundation of Chongqing, China; MSC-exosome was used to study the interaction between TGF-β and Wnt signaling pathway in chronic allograft neph…, The doctoral program of the first affiliated hospital of Chongqing Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SirolimusAdverse Drug Reaction Reporting SystemsMTOR InhibitorsAntineoplastic AgentsDrug-Related Side Effects and Adverse ReactionsUnited States Food and Drug AdministrationUnited StatesHumansDatabases, FactualBayes TheoremFemale

Stichwörter der Autor:innen

Adverse eventsFDA adverse event reporting systemMTORRenal cell carcinomaTemsirolimus

Substanzen

temsirolimusSirolimusMTOR InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China.
  • Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China. sushuai930809@163.com.
  • Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China. yinzhikang2005@sina.com.

Förderung

  • Natural Science Foundation of Chongqing, China; MSC-exosome was used to study the interaction between TGF-β and Wnt signaling pathway in chronic allograft neph…
  • The doctoral program of the first affiliated hospital of Chongqing Medical University

Zitieren

APA

Dan, L., Liu, Z., Zhao, Z., Ran, Y., Zhou, J., Li, D., Zhou, R., Su, S., & Yin, Z. (2026). Temsirolimus safety evaluation: real-world adverse event analysis from the FDA adverse event reporting system database. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(9), 13661-13676. https://doi.org/10.1007/s00210-026-05233-9

Vancouver

Dan L, Liu Z, Zhao Z, Ran Y, Zhou J, Li D, et al. Temsirolimus safety evaluation: real-world adverse event analysis from the FDA adverse event reporting system database. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(9):13661-13676. doi:10.1007/s00210-026-05233-9

BibTeX
@article{Dan2026,
  author = {Dan, Lifeng and Liu, Zhenyu and Zhao, Zecang and Ran, Yueli and Zhou, Jiangtao and Li, Dongyang and Zhou, Renjie and Su, Shuai and Yin, Zhikang},
  title = {Temsirolimus safety evaluation: real-world adverse event analysis from the FDA adverse event reporting system database},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  volume = {399},
  number = {9},
  pages = {13661--13676},
  doi = {10.1007/s00210-026-05233-9}
}
Kostenlos starten →